PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say

PTC Therapeutics (PTCT) reported $178.88 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 4.2%. EPS of -$0.83 for the same period compares to -$1.16 a year ago.

The reported revenue represents a surprise of +4.82% over the Zacks Consensus Estimate of $170.66 million. With the consensus EPS estimate being -$1.07, the EPS surprise was +22.43%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how PTC Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Net product revenue: $118.33 million compared to the $116.13 million average estimate based on five analysts. The reported number represents a change of -11.2% year over year.
• Revenues- Royalty revenue: $57.61 million versus $54.34 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8.3% change.
• Revenues- Net product revenue- Translarna: $59.5 million versus $45.73 million estimated by four analysts on average.
• Revenues- Net product revenue- Emflaza: $36.4 million versus $45.03 million estimated by four analysts on average.
• Revenues- Collaboration and license revenue: $2.94 million compared to the $5.25 million average estimate based on two analysts.

View all Key Company Metrics for PTC Therapeutics here>>>

Shares of PTC Therapeutics have returned +5.4% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
PTC Therapeutics, Inc. (PTCT): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research